Public Health England has launched a nationwide ‘Be Clear on Cancer’ campaign with the aim of raising awareness of a key symptom for both bladder and kidney cancers – blood in pee.
ConclusionEvolution and prognosis evaluation remain hard and could necessitate a radical surgery. Prognosis criteria for the bladder PEComas have to be clarified.
Publication date: Available online 9 August 2018Source: Actas Urológicas Españolas (English Edition)Author(s): J.A. March-Villalba, J. Panach-Navarrete, M.J. Herrero-Cervera, S. Aliño-Pellicer, J.M. Martínez-JabaloyasAbstractIntroductionTo study the relationship between quantitative mRNA determination (hTERT) in patients with bladder tumor, history of bladder tumor, and in subjects without a history of this neoplasia.Material and methodsA prospective randomized controlled study with 91 subjects included. The value of mRNA-hTERTN was determined in 63 patients with a history or suspicion of bladde…
Publication date: Available online 9 August 2018Source: Actas Urológicas Españolas (English Edition)Author(s): F. Gómez-Veiga, A. Alcaraz-Asensio, J. Burgos-Revilla, J. Cózar-OlmoAbstractObjectiveTo put forth new findings of urologic oncology with an impact on clinical practice presented during 2017 in the main annual meetings.MethodsThis document reviews abstracts on prostate, kidney and bladder cancer presented at the congresses of 2016 (EAU, AUA, ASCO, ESMO and ASTRO) and publications with the highest impact in this period valued with the highest scores by the OncoForum committee.ResultsAmong…
Publication date: 9 August 2018Source: Cell, Volume 174, Issue 4Author(s): A. Gordon Robertson, Jaegil Kim, Hikmat Al-Ahmadie, Joaquim Bellmunt, Guangwu Guo, Andrew D. Cherniack, Toshinori Hinoue, Peter W. Laird, Katherine A. Hoadley, Rehan Akbani, Mauro A.A. Castro, Ewan A. Gibb, Rupa S. Kanchi, Dmitry A. Gordenin, Sachet A. Shukla, Francisco Sanchez-Vega, Donna E. Hansel, Bogdan A. Czerniak, Victor E. Reuter, Xiaoping Su
This study provides a dendritic cell-based vaccine strategy which might reduce the risk of tumor recurrence and improve the efficiency of anti-chemoresistance of bladder cancer.
PMID: 30084800 [PubMed – in process]
An existing body of literature shows that marital status and related social support are connected with disease outcomes.
Conclusion: Sarcopenia is present in a considerable proportion of patients with MIBC undergoing upfront cisplatin-based chemotherapy before planned RC. SMI decreases during treatment, but neither baseline SMI nor its kinetics is associated with response to chemotherapy.Urol Int 2018;101:1 –4
Condition: Safety Issues Intervention: Drug: Atezolizumab Sponsor: McGill University Health Center Recruiting
Authors: Creighton CJ
INTRODUCTION: Knowledge of the molecular subtypes of bladder cancer enables powerful generalizations involving the distinctive biology and pathways driving different disease subsets. Areas Covered: In this review, we summarize the findings of a number of published studies exploring the molecular landscape of bladder cancer by analysis of genomic data from The Cancer Genome Atlas (TCGA). TCGA project has provided a comprehensive data resource of 412 muscle-invasive bladder cancers as characterized by multiple molecular analytical platforms. These data have been and will continue to be …
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including the novel agent erdafitinib as a treatment targeting fibroblast growth factor receptor (FGFR) alterations in muscle-…